STO · SOBI.ST
Swedish Orphan Biovitrum AB
SEK 488.00+SEK 9.80 (+2.05%)
Swedish Orphan Biovitrum AB’s quoted price sits in the upper half of its reported 52-week range, 0.81% below the high.
Loading market information…
STO · CAMX.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 04:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Camurus AB’s quoted price sits in the upper half of its reported 52-week range, 5.63% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Camurus AB’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of SEK 3.71. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Camurus AB’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud’s phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM2056 that is in phase I clinical trials for the treatment of metabolic diseases; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity; and Gubra A/S to develop long-acting therapeutic option for the treatment of hypoparathyroidism; as well as NewBridge Pharmaceuticals. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:57 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 15, 2025 | SEK 3.23+14.54% vs estimate | SEK 558.34M-3.97% vs estimate |
|---|
| Q4 2024 | Feb 13, 2025 | SEK 2.45+59.09% vs estimate | SEK 553.13M-7.96% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | SEK 2.16+47.95% vs estimate | SEK 479.60M-11.44% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 488.00+SEK 9.80 (+2.05%)
Swedish Orphan Biovitrum AB’s quoted price sits in the upper half of its reported 52-week range, 0.81% below the high.
SEK 319.40-SEK 0.80 (-0.25%)
BioArctic AB’s quoted price sits in the upper half of its reported 52-week range, 12.35% below the high.
SEK 10.34SEK 0.00 (0.0%)
Egetis Therapeutics AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 4.44% below the high.
SEK 39.34+SEK 0.64 (+1.65%)
Hansa Biopharma AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 18.42% below the high.
SEK 9.90+SEK 0.40 (+4.21%)
Vicore Pharma Holding AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 45.72% below the high.
SEK 11.45-SEK 0.05 (-0.43%)
Saniona AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 59.54% below the high.
SEK 1.61+SEK 0.00 (+0.12%)
Medivir AB’s quoted price sits in the lower half of its reported 52-week range, 44.19% below the high.
SEK 68.30+SEK 0.40 (+0.59%)
Infant Bacterial Therapeutics AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 19.55% below the high.
